Gilead Sciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GILD Nasdaq 2830 www.gilead.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gilead Sciences, Inc.

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer - Dec 12th, 2024 10:54 pm
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer - Dec 12th, 2024 10:30 pm
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing - Dec 12th, 2024 6:13 pm
Is Gilead Sciences (GILD) Stock Undervalued Right Now? - Dec 12th, 2024 2:40 pm
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Dec 12th, 2024 2:00 pm
Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers - Dec 12th, 2024 12:00 pm
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group - Dec 10th, 2024 10:00 am
Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy - Dec 9th, 2024 10:57 pm
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024 - Dec 9th, 2024 10:45 pm
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits - Dec 9th, 2024 9:30 pm
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - Dec 9th, 2024 9:22 pm
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences - Dec 9th, 2024 8:15 pm
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH - Dec 8th, 2024 5:30 pm
Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying. - Dec 5th, 2024 9:00 am
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC - Dec 4th, 2024 3:09 pm
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy - Dec 3rd, 2024 4:27 pm
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Dec 3rd, 2024 2:30 pm
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target - Dec 3rd, 2024 12:00 pm
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell? - Nov 29th, 2024 6:50 pm
GILD vs. VRTX: Which Stock Should Value Investors Buy Now? - Nov 29th, 2024 4:40 pm